James Rolke, Revelation Biosciences CEO
July 25, 2022 07:37 AM EDTUpdated 08:36 AM
R&D

Four months af­ter first in­tranasal flunks in­fluen­za test, Rev­e­la­tion's sec­ond-gen as­set miss­es on ef­fi­ca­cy

Kyle LaHucik

Senior Reporter

Rev­e­la­tion Bio­sciences had big plans for 2022 af­ter go­ing pub­lic via a SPAC in Jan­u­ary and al­so rais­ing $7.7 mil­lion in PIPE fi­nanc­ing lat­er that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times